XML 26 R14.htm IDEA: XBRL DOCUMENT v3.7.0.1
Marketable Securities
6 Months Ended
Jun. 30, 2017
Cash and Cash Equivalents [Abstract]  
Marketable Securities
Marketable Securities
A summary of the Company’s cash, cash equivalents and marketable securities is shown below:
 
Amortized Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Fair Value
 
(in thousands)
As of June 30, 2017
 
 
 
 
 
 
 
Cash and cash equivalents:
 
 
 
 
 
 
 
Cash and money market funds
$
1,217,134

 
$

 
$

 
$
1,217,134

Commercial paper
5,996

 

 

 
5,996

Total cash and cash equivalents
$
1,223,130

 
$

 
$

 
$
1,223,130

Marketable securities:
 
 
 
 
 
 
 
Corporate equity securities
43,213

 
7,836

 

 
51,049

Commercial paper (matures within 1 year)
103,386

 
1

 
(40
)
 
103,347

Corporate debt securities (matures within 1 year)
218,216

 
4

 
(143
)
 
218,077

Corporate debt securities (matures after 1 year)
73,115

 
2

 
(70
)
 
73,047

Total marketable securities
$
437,930

 
$
7,843

 
$
(253
)
 
$
445,520

Total cash, cash equivalents and marketable securities
$
1,661,060

 
$
7,843

 
$
(253
)
 
$
1,668,650

 
 
 
 
 
 
 
 
As of December 31, 2016
 
 
 
 
 
 
 
Cash and cash equivalents:
 
 
 
 
 
 
 
Cash and money market funds
$
1,183,945

 
$

 
$

 
$
1,183,945

Total cash and cash equivalents
$
1,183,945

 
$

 
$

 
$
1,183,945

Marketable securities:
 
 
 
 
 
 
 
Government-sponsored enterprise securities (matures within 1 year)
$
15,506

 
$
2

 
$

 
$
15,508

Corporate equity securities
43,213

 
21,347

 

 
64,560

Commercial paper (matures within 1 year)
59,331

 
73

 

 
59,404

Corporate debt securities (matures within 1 year)
111,225

 

 
(85
)
 
111,140

Total marketable securities
$
229,275

 
$
21,422

 
$
(85
)
 
$
250,612

Total cash, cash equivalents and marketable securities
$
1,413,220

 
$
21,422

 
$
(85
)
 
$
1,434,557


The Company has a limited number of marketable securities in insignificant loss positions as of June 30, 2017, which the Company does not intend to sell and has concluded it will not be required to sell before recovery of the amortized costs of the investment at maturity. There were no charges recorded for other-than-temporary declines in fair value of marketable securities nor gross realized gains or losses recognized in the three and six months ended June 30, 2017 and 2016.